Skip to content
Menu

Sol-Gel Technologies Ltd. SLGL

Full chart Compare
Set alert

Price alert · SLGL

All alert types
55.17 USD +1.09 (+2.02%)

Regular-session close

56.27 +1.10 +1.99%

After hours · Nov 20, 4:00 PM ET

51.81 Day range 56.16
35.75 52-week range 97.97
YTD
+30.92%
1 year
+54.32%

5D -0.74 (-1.32%)

52545658MonTueWedThuFri55.17
Market cap
180.63M
Revenue (ttm)
6.56M
Profit margin
-227.40%
EPS (ttm)
-5.22
Shares out
27.86M
Forward P/E
-3.44
YTD return
+30.92%
1-year return
+54.32%
Volume
24.67K
Avg volume
47.52K
Open
52.43
Previous close
54.08
Day's range
51.81 – 56.16
52-week range
35.75 – 97.97
Beta
1.60
Price target
5.00 (-90.9%)

Key statistics

50-day average
0.55476
200-day average
0.70915
Enterprise value
-14.73M
Price / sales
7.01
Price / book
1.19
Revenue growth
814.60%
Free cash flow
-12.43M
Total cash
30.47M
Total debt
1.39M
Return on equity
-35.85%
Short % of float
0.31%

Fundamental scorecard

4 of 25 checks passed on SLGL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
SLGL Revenue — quarterly 41.00K
SLGL Net income — quarterly -5.62M
SLGL EPS — quarterly -1.72

Earnings

SLGL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 15, 2024Sep 1, 2024-0.13-0.01+0.12+92.31%
Aug 16, 2024Jun 1, 2024-0.200.07+0.27+135.00%
Aug 16, 2024Jun 1, 2024-0.20———
May 20, 2024Mar 1, 2024-0.15-0.23-0.08-53.33%
May 20, 2024Mar 1, 2024-0.15———
Mar 13, 2024Dec 1, 2023-0.16———

Upgrades / downgrades

SLGL analyst upgrades and downgrades
DateFirmActionFromTo
Aug 19, 2024Raymond JamesdownStrong BuyOutperform
May 22, 2024HC Wainwright & Co.reitBuyBuy
May 20, 2024HC Wainwright & Co.mainBuyBuy
Nov 13, 2023HC Wainwright & Co.mainBuyBuy
Aug 14, 2023HC Wainwright & Co.mainBuyBuy
Aug 11, 2023Raymond JamesmainStrong BuyStrong Buy

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
sol-gel.com

News

Your note

Sign in to keep a note on SLGL — it syncs with the Stock Master app.

Institution ownership

SLGL institution ownership
Holder% heldSharesValueReported
Phoenix Holdings Ltd.8.87%2,470,1924.08MSep 29, 2024
Migdal Insurance & Financial Holdings Ltd.4.41%1,227,5482.03MSep 29, 2024
Harel Insurance Investments & Financial Services Ltd.3.30%920,3331.52MSep 29, 2024
Yelin Lapidot Holdings Management Ltd.0.82%229,178378.14KSep 29, 2024
Prosperity Wealth Management, Inc. 0.59%163,400269.61KSep 29, 2024
Raymond James Financial Services Advisors, Inc.0.32%88,461145.96KSep 29, 2024

Fund ownership

SLGL fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%13,40622.12KOct 30, 2024